Abstract Caseinophosphopeptides (CPPs) are phosphorylated casein-derived peptides which possess the ability to bind and solubilise minerals, such as Ca2+. Consumption of high concentrations of Ca2+ in early life contributes to the development of maximal bone density, which in turn can prevent osteoporosis in later life. Furthermore, a recent report has shown a positive correlation between Ca2+ intake and the prevention of hypertension. The high bioavailability of Ca2+ from milk and dairy products has, in part, been attributed to the production of CPPs which have different levels of phosphorylation and are produced in vivo following digestion of α s 1 -, α s 2 - and β-casein by the action of gastrointestinal proteinases. CPPs which appear to be resistant to extensive proteolytic degradation, accumulate in the distal small intestine where they are purported to play a role in enhancing the passive absorption of Ca2+ and other trace elements. CPPs have also been produced in vitro using a range of commercially available proteinases of pancreatic origin. Several CPP enrichment procedures from casein hydrolysates have been reported, generally involving Ca2+ induced aggregation followed by ultrafiltration. These CPP enriched preparations have been used to characterise their interaction with Ca2+ and trace elements and to determine their effect on the bioavailability of dietary Ca2+ during animal and human feeding trials. There are conflicting reports, arising from the results of animal feeding studies, on the effectiveness of CPPs in enhancing Ca2+ bioavailability. However, a recent human feeding trial reported improved Ca2+ and Zn2+ absorption following CPP incorporation into a rice-based infant food. In vitro produced CPPs may also find application in the prevention and treatment of dental calculus. This review summarises the production, characterisation and potential applications of CPPs.
Read full abstract